{"id":"W2140338938","doi":"10.1158/1078-0432.ccr-05-0262","title":"Phase I Trial of a Monoclonal Antibody Specific for αvβ3 Integrin (MEDI-522) in Patients with Advanced Malignancies, Including an Assessment of Effect on Tumor Perfusion","year":2005,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cell Adhesion Molecules Research","field":"Medicine","cited_by":158,"is_retracted":false,"has_abstract":true,"ca_institutions":"Immunovaccine (Canada)","funders":"National Center for Research Resources; National Cancer Institute","keywords":"Medicine; Adverse effect; Response Evaluation Criteria in Solid Tumors; Asymptomatic; Cancer; Metastasis; Pathology; Internal medicine; Oncology; Phases of clinical research; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006329474,0.0002189292,0.0009583925,0.0004557365,0.00008721982,0.00001675014,0.000370808,0.0001516971,0.0003598738],"category_scores_gemma":[0.001700403,0.0001557108,0.0001966956,0.000748724,0.0005023808,0.0001100005,0.0002296897,0.001312868,0.000004492123],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005847277,"about_ca_system_score_gemma":0.000978783,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001027617,"about_ca_topic_score_gemma":0.00008983594,"domain_scores_codex":[0.9942356,0.0008795577,0.001187131,0.000743655,0.002286215,0.0006677792],"domain_scores_gemma":[0.9950652,0.002665675,0.0002435918,0.000654531,0.0009842805,0.0003867503],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4923991,0.01397309,0.1073875,0.0004301672,0.0000544685,0.00004215457,0.00009390183,0.00008349562,0.06692138,0.00005590947,0.0006631969,0.3178957],"study_design_scores_gemma":[0.4547315,0.2394605,0.2360437,0.002499955,0.00004422171,0.000001538793,0.0001368214,0.003541118,0.0565769,0.00003470803,0.006585769,0.000343331],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9943231,0.0001184435,0.00009533888,0.0003142398,0.0001337903,0.004628132,0.00007166256,0.00001225088,0.0003030492],"genre_scores_gemma":[0.9961641,0.0002209561,0.002414083,0.00005114878,0.0004320309,0.000412768,0.0001345319,0.00005007723,0.0001202965],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3175523,"threshold_uncertainty_score":0.6349704,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1781517426797625,"score_gpt":0.588530311715438,"score_spread":0.4103785690356755,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}